A secondary analysis of the PROMISE III trial has shown that in patients with chronic limb-threatening ischemia (CLTI) who ...
New data from the PROMISE III trial show the LimFlow transcatheter deep venous arterialization system achieved over 80% amputation-free survival at six months in 'no-option' chronic limb-threatening ...
Data from the PROMISE III trial suggest that chronic limb-threatening ischemia (CLTI) patients with no other treatment ...
COLLEGE STATION, Texas (KBTX)- This segment on The Three was paid for and sponsored by Davis Vein & Vascular. Davis Vein & Vascular is now offering a procedure aimed at saving the limbs of patients ...
Data from the PROMISE III trial suggest that chronic limb-threatening ischemia (CLTI) patients with no other treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results